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PURPOSE: The aim of this study was to investigate estrogen’s effect on markers of 
muscle damage and the repeated bout effect in women following multiple downhill runs. 
METHODS: Thirteen moderately trained females (VO2 max: 36-47 ml/kg/min), 18-35 
years old, and who used hormonal contraception participated in the study. They 
completed two 40 min downhill runs (-10% grade) at 65-70% VO2 max during either the 
third week of hormone use (low estrogen group (LE), n=7) or the placebo week (high 
estrogen group (HE), n=6). Trials were separated by four weeks. Creatine kinase (CK) 
activity, pressure tolerance (front thigh, shin, and calf), and circumferences (thigh and 
calf) were measured before (pre) and at 24 hr, 48 hr, and 72 hr after exercise. Muscle 
soreness of the front thigh, shin and calf was reported immediately (0 hr) and at 24 hr, 48 
hr, and 72 hr after exercise. Knee extension and ankle dorsiflexion peak torque were 
measured pre and 72 hr postexercise. RESULTS: A run effect was found in front thigh (P 
= 0.009) and calf (P = 0.02) pressure tolerance such that DH1 was lower than DH2. 
Soreness of the front thigh was lower following DH2 compared to DH1 (P = 0.05). A 
group x time interaction was observed for shin soreness such that soreness in LE was 




(P < 0.01; P = 0.04, respectively). Following DH1, CK activity was higher at 24 hr (P < 
0.001), 48 hr (P = 0.04), and 72 hr (P = 0.03) compared to pre-exercise.  CK activity was 
lower at 24 hr following DH2 (P < 0.001) compared to 24 hr following DH1.  No 
significant changes were noted for shin pressure tolerance, calf soreness, circumference, 
or peak torque measurements. CONCLUSION: Women with lower estrogen levels may 
show a greater response in markers of muscle damage following the initial bout of 
exercise as evidenced by increased soreness in the shin. The RBE was observed as 
evidenced by a less robust response to pressure tolerance, soreness and CK activity 
following DH2, with no group differences in the RBE response. Higher estrogen levels at 
the time of exercise may mitigate markers of muscle damage following an initial bout of 





CHAPTER 1. INTRODUCTION 
 Introduction 1.1
Eccentric exercise is characterized by a lengthening of the muscle while it 
produces force in an attempt to shorten. This type of work done on the muscle by forced 
external lengthening often leads to muscle damage if the muscle is unaccustomed to the 
exercise (Armstrong 1984, Byrnes et al. 1985, Friden et al. 1981).  Indeed, eccentric 
exercise induces more muscle damage compared to concentric exercise (Armstrong 1984) 
possibly due to metabolic and/or mechanical stress (Ebbeling and Clarkson 1989, 
Armstrong 1990). There are five general characteristics of muscle damage: muscle fiber 
disarrangement, decreased muscle performance, muscle protein release into the blood, 
delayed onset muscle soreness (DOMS), and an acute-phase immune response (Stupka et 
al. 2000).   
Muscle damage results in muscle fiber disarrangement such as z-disc disruptions 
(Friden et al. 1981, Armstrong 1984) which are visible in muscle biopsy samples. A 
limitation of biopsies, however, is that it is possible to miss damaged fibers when the 
biopsy is taken, or induce more damage to the surrounding muscle which may 
compromise ensuing biopsies (Malm 2001). 
Muscle force production decreases immediately after muscle-damaging eccentric 




2008). Recovery may take as little as three days to more than ten days (Kerksick et al. 
2008, Eston et al. 2000) depending on exercise intensities and protocols (Kerksick et al. 
2008, Eston et al. 2000, Nosaka et al. 2002).  
Due to disruption of the muscle membrane, proteins [e.g. creatine kinase (CK)] 
are able to leak out into the blood. Elevated plasma (Chen 2006, Van Der Meulen et al. 
1991) or serum (Sewright et al. 2008, Thompson et al. 1997) CK activity is commonly 
used as an indicator of damage (Chen 2006). It should be noted, however, that the 
increase in enzyme concentration is not necessarily proportional to the amount of muscle 
damage (Van Der Meulen et al. 1991).  Values also show high intersubject variability 
(Chen 2006).  
Delayed onset muscle soreness (DOMS) is soreness that does not appear 
immediately post exercise, but rather a day or two later. While the direct cause of DOMS 
is unknown, it is associated with swelling and decreased muscle performance (Chleboun 
1998). DOMS usually peaks one to three days after exercise and may persist for up to 
seven days (Friden et al. 1981, Armstrong 1984). 
Following muscle damaging exercise, leukocytes (neutrophils and macrophages) 
migrate to the area to remove dead and damaged cells and to promote the repair process. 
This is known as an acute-phase immune response (Field et al. 1991, Tidball 2005). 
While a necessary part of the repair process, it can also lead to more damage in the 
surrounding tissue through the release of reactive oxygen species (ROS) by these cells 
(Tidball 2005). 
There is evidence, albeit somewhat inconsistent, of sex differences in the muscle 




female rats have been found in multiple studies (Bar et al. 1988, Amelink et al. 1990, Van 
Der Meulen et al. 1991, Komulainen et al. 1999). For example, markers of muscle 
damage (β-glucuronidase, CK) were lower in female compared to male rats following a 
downhill running protocol (Bar et al. 1988, Komulainen et al. 1999). Additionally, 
swelling and loss of structural proteins from the muscle cell appear to be greater and 
appear sooner in male rats and is hypothesized to be due to greater sarcolemma disruption 
(Komulainen et al. 1999). In comparison to women, men show greater muscle soreness, 
strength loss, and muscle protein leakage (Kerksick et al. 2008), but these findings are 
not consistently reported (Sewright et al. 2008, Stupka et al. 2000). 
Estrogen is being investigated as a possible explanation for the observed gender 
differences in muscle damage. Estrogen is a group of steroid hormones that contains 
eighteen carbon atoms and is derived from cholesterol (Johnson 2007, Tortora and 
Derrickson 2009). There are three forms of estrogen: 17-β estradiol, estrone, and estriol. 
Estrogen is produced mainly by the ovaries with some production from the adrenal 
glands. While often referred to as the female sex hormone, estrogen is also produced in 
males but in significantly lower concentrations (Johnson 2007).  
Estrogen concentrations vary throughout a woman’s menstrual cycle. Estrogen 
levels are low during the early follicular stage when menstruation is occurring. During 
the follicular stage, the follicle (which contains the developing oocyte) begins to grow 
and eventually starts to produce estrogen. This results in a continual increase in estrogen 
levels in the body, with an additional surge of estrogen just prior to ovulation.  Following 
ovulation is the luteal stage. Estrogen levels in the luteal phase decrease after the surge 




decline and menstruation occurs (Johnson 2007, Tortora and Derrickson 2009). The 
average cycle (starting with the first day of menses and ending the day prior to 
menstruation) is approximately 28 days, with most cycles occurring between 25 and 31 
days (Chiazze et al. 1968). 
Estrogen’s role in mediating muscle damage is not well understood but it may 
protect the muscle through its ability to act as an antioxidant, membrane stabilizer, or 
gene regulator (Kendall and Eston 2002).  Evidence for estrogen decreasing muscle 
damage has been demonstrated in rats. When male rats and ovariectomized female rats 
were given estrogen supplementation, markers of muscle damage were lower and 
followed the pattern of female intact rats (Bar et al. 1988, Tiidus et al. 2001). In humans, 
Carter et al. (2001) found a decrease in plasma CK activity with no difference in muscle 
soreness when estrogen levels were different between two female groups (Carter et al. 
2001).  Thompson et al. (1997) found the opposite, i.e. a difference in muscle soreness, 
but no significant change in CK. Both studies included hormonal contraceptive (HC) 
users versus non HC users. It should be noted that the effect of exogenous versus 
endogenous estrogen on muscle damage has not been thoroughly studied (Savage and 
Clarkson 2002). While both Thompson et al. (1997) and Carter et al. (2001) used 
eccentric exercise to induce muscle damage in each study, different protocols (aerobic 
versus anaerobic) were used which may have contributed to the contradictory findings.  
 An area of research that has not been explored is the effect estrogen levels have 
on the repeated bout effect (RBE). After completion of an initial bout of eccentric 
exercise, markers of muscle damage are not as apparent following a second exercise bout 




soreness, and muscle fiber disruption following a second bout of eccentric exercise 
characterize the RBE (Newham et al. 1987, Byrnes et al. 1985). The cause of this 
attenuation of markers of muscle damage is unknown. It has been proposed that cellular 
changes, neuronal changes, and/or mechanical changes are occurring (McHugh 2003). 
Regarding sex differences, the pattern of RBE in women is similar to what has been 
described in men (Stupka et al. 2001, Fernandez-Gonzalo et al. 2011). 
 
 Statement of the problem 1.2
The lack of clarity concerning estrogen and its role in protecting against muscle 
damage is primarily due to the lack of research in this area and the variability in estrogen 
among women. Not every woman has a 28 day menstrual cycle and hormone 
concentrations will vary not only throughout the cycle but also among women (Treloar et 
al. 1967, Chiazze et al. 1968). HC use among women could also affect markers of muscle 
damage. There is some evidence that HC may have a beneficial effect on muscle soreness 
(Kendall and Eston 2002) and strength recovery (Savage and Clarkson 2002) after 
exercise.  
Generally, two types of eccentric exercise are used to induce muscle damage: 
downhill running and isolated muscle contractions. While isolated muscle contractions 
focus on a single type of movement to localize damage to a specific area, downhill 
running affects several major muscle groups. Different methods of exercise used in the 
studies by Carter et al. (2001) and Thompson et al. (1997) (downhill running and bench 
stepping, respectively) may be a factor in the contradicting muscle soreness and CK 




Currently there is no literature that specifically examines the question of estrogen 
and its influence on the RBE. Muscle damage induced during the first bout of exercise 
may be the trigger that leads to adaptations to protect the muscle from future damage. If 
estrogen can attenuate muscle damage resulting from the first exercise bout, there is some 
uncertainty as to if and how that may affect the RBE.  
 
 Aims and Hypotheses 1.3
Aim 1: To determine if estrogen levels at the time of exercise influence the ensuing 
muscle soreness and CK response. 
Ho: Higher estrogen levels at the time of exercise will not attenuate the ensuing muscle 
soreness and CK response to a bout of eccentric exercise compared to a lower estrogen 
level. 
Ha: Higher estrogen levels at the time of exercise will attenuate muscle soreness and CK. 
 
Aim 2: To determine if estrogen levels at the time of exercise will change markers of 
the repeated bout effect. 
Ho: There will be no difference in the attenuation of CK and soreness between high and 
low estrogen groups following a second bout of eccentric exercise. 
Ha: There will be a smaller attenuation of CK and soreness following the second bout in 







There are several limitations to this study. Muscle biopsies were not performed to 
confirm the extent of muscle damage. Our subject pool included only HC users, so 
responses in women who do not use HC are unknown. Only moderately trained women 
were included in this study, therefore, extrapolation of the results to other populations 





CHAPTER 2. LITERATURE REVIEW 
 Introduction 2.1
Estrogen is a group of hormones commonly referred to as the female sex hormone, 
although men also have estrogen albeit in much lower concentrations (Johnson 2007). 
While estrogen is known to play a role in development and reproduction, its significance 
in protecting against muscle damage is less defined. Animal studies have demonstrated 
that high estrogen levels decrease markers of muscle damage (Bar et al. 1988). Similar 
results have been reported in humans but they have not been consistent across studies 
(Kerksick et al. 2008, Stupka et al. 2000). There is a lack of research on the role of 
estrogen in the repeated bout effect (RBE) in women. RBE is characterized by a decrease 
in muscle damage and soreness but any interaction between RBE and estrogen is 
unknown. 
 
 Eccentric Exercise 2.2
Eccentric contractions occur when the muscle lengthens while producing force, i.e. 
resistance or force is applied to a muscle that is increasing in length while exerting 




damage to skeletal muscle tissues compared to concentric (muscle shortening) 
contractions (Armstrong 1984, Chleboun 1998). Mechanical and metabolic stressors 
produced by eccentric contractions may trigger the initiation of exercise induced muscle 
damage. Mechanical stress (damage to the sarcolemma, sarcoplasmic reticulum, and 
muscle fiber structures) and metabolic stress (high temperature, decreased ATP levels, 
ROS, and lower pH) can lead to a disruption in calcium homeostasis in muscle cells 
(Armstrong 1990). Damage to the sarcomeres and/or sarcolemma results in muscle 
soreness and/or pain, leakage of muscle proteins into the blood, and decreased strength in 
the days following a bout of eccentric exercise (Clarkson and Trembley 1988).  
 
 Creatine Kinase 2.3
The disruption of muscle fiber structures leads to the leakage of muscle cell 
contents, some of which are used as indirect markers that muscle damage has occurred. 
Examples are myoglobin (Armstrong 1984), intracellular calcium concentration (Sonobe 
et al. 2010), and IL-6 (Chaffin et al. 2011), with the most commonly measured being CK 
activity (Thompson et al. 1997, Carter et al. 2001, Stupka et al. 2000). CK is found in 
muscle and in some organs (Amelink et al. 1988) and is released into the blood when 
muscle tissue is damaged (Chen 2006).  CK is an enzyme that catalyzes the formation of 
phosphocreatine and adenosine diphosphate from creatine and adenosine triphosphate 
(ATP) in the cells. CK also catalyzes the reverse reaction to create ATP (Wallimann et al. 
1992). While not a direct marker, an increase in plasma CK activity after exercise is 




Large variability exists in the CK response to exercise among individuals.  Chen 
(2006) found that males who were divided into groups based on plasma CK response 
(low, medium and high responders) following an initial bout of eccentric exercise showed 
a similar response in plasma CK levels a year later. This indicates that people are 
naturally high or low CK responders and may explain some of the variability in plasma 
CK values.  
In addition to being low or high responders, sex may also influence CK values. 
Rat studies show that intact females tend to have lower levels of CK activity at rest 
compared to their male (Bar et al. 1988) and ovariectomized counterparts (Bar et al. 1988, 
Tiidus 2001 et al.). However, when resting values of plasma CK were similar, Amelink et 
al. (1988) found a greater increase in male rats compared to females following two hours 
of running. In humans, Stupka et al. (2000) showed in an underpowered study that the 
data was trending towards a significant gender difference in CK values following 
exercise (p=0.14) with women tending to have lower levels of CK .  When comparing 
men and women after downhill running, Eston et al. (2000) did not find sex differences in 
CK levels. 
The benefits of using CK as a marker of muscle damage is that it is easy to 
measure and there is a vast collection of literature for comparison. The drawbacks to 
using CK are that there is large intersubject variability (Chen 2006) and a correlation has 
not been established between the extent of muscle damage and plasma CK activity (Van 





 Delayed-onset muscle soreness 2.4
As previously mentioned, unaccustomed eccentric exercise produces soreness in 
the muscles which generally peaks 24-72 hours after exercise (Friden et al. 1981, 
Newham et al. 1987, Smith et al. 1994) and dissipates approximately 4-7 days after 
exercise (Hough 1902, Armstrong 1984). This is commonly referred to as delayed onset 
muscle soreness or DOMS. Although DOMS has been found in the distal part of the 
muscle after exercise, it is generally located throughout the whole muscle when maximal 
exercise is performed. The localization of soreness in the distal end could be due to the 
damage being focused in that area or pain receptors being located in the distal end of the 
muscle near the tendons (Armstrong 1984). The cause of DOMS is unknown but is 
associated with swelling (Chleboun 1998), decreased muscle performance (Smith et al. 
1994, Chleboun 1998), and muscle damage in the exercised muscle (Armstrong 1984). 
Swelling is often determined by comparing the circumference of the limb before 
and after exercise. While measuring changes in circumference does not indicate where 
the swelling is occurring (e.g. in the muscles or surrounding tissue), it indicates that 
volume is increasing in that area (Nosaka et al. 2002, Chleboun 1998).  Chleboun (1998) 
found that muscle circumference was the largest four days after performing isolated 
eccentric elbow flexor.  The increase in volume was as much as 26%, and returned to pre-
exercise values approximately nine days after exercise. 
Decreased muscle performance is often associated with muscle soreness. The 
decreased ability to produce force could be caused by an unwillingness to fully contract 
the muscle due to increased pain or because the contractile units are too damaged to 




exercise force production usually takes about two weeks (Newham et al. 1987). Chelboun 
et al. (1998) found that muscle performance decreased by as much as 47% of voluntary 
maximal contraction following eccentric exercises of the elbow flexors. The greatest 
decrease in performance was observed one day following exercise and was yet to be fully 
recovered ten days after exercise. 
To determine muscle damage, indirect measures such as protein (e.g. CK activity) 
in the blood and direct measures such as muscle biopsies are used. Muscle biopsies give a 
direct view of muscle tissue; however, muscle biopsies only show a small segment of 
muscle tissue, and the section observed may or may not be taken from tissue that is 
damaged. The process of taking the biopsy can also damage the surrounding tissue and 
may confound results if another sample is taken from the compromised surrounding area 
(Malm 2001). 
 
2.4.1 Possible Mechanisms 
The dull pain associated with DOMS may be due to nerves being stimulated by a 
chemical signal (e.g., from molecules such as bradykinins), mechanical pressure from 
swelling, or a thermal change caused by increased temperature associated with 
inflammation. Armstrong (1984) proposed a model for DOMS starting with disruption of 
the muscle fibers due to the mechanical stress of the exercise, particularly eccentric 
exercise. Damage to the muscle fibers results in increased calcium in the cells. The 
calcium imbalance eventually leads to the destruction of the cell, ultimately releasing 




After muscle-damaging exercise and the ensuing leakage of cellular contents such 
as calcium, an inflammatory response is triggered to repair the damaged tissue. The 
inflammatory response may be activated by calpain (calcium-activated) which attracts 
neutrophils to the area through chemo-attractants (Belcastro et al. 1998). Neutrophils and 
macrophages migrate to the site to clean-up the muscle tissue. This inflammatory process 
itself can lead to more muscle damage. For example, neutrophils release ROS or factors 
that increase the levels of ROS while cleaning up debris from the original damage which 
can lead to more tissue damage (Kendall and Eston 2002).  While it is not believed that 
neutrophils contribute directly to muscle repair, it could be that removal of damaged 
tissue by neutrophils can help the regeneration process continue. Other phagocytic cells 
(i.e., macrophages) also migrate to the area to clean up debris and could also be involved 
with the repair process itself (Tidball 2005, Tiidus et al. 2001).  Therefore, while a 
decrease in the number of neutrophils and macrophages that invade the area may reduce 
the amount of additional damage that occurs, it may also hinder the regeneration process. 
 
 Repeated Bout Effect 2.5
One bout of eccentric exercise produces a protective effect whereby a second bout 
of the same exercise results in less muscle damage and soreness. This phenomenon is 
termed the repeated bout effect (RBE), and is characterized by less muscle disruption, 
lower CK levels (Byrnes et al. 1985), decreased soreness, and an attenuated leukocyte 
response. These adaptations are seen only if the repeated bout is performed within a 
certain time frame after the first exercise bout. Smith et al. (1994) found that if the second 




an initial single bout of exercise (Smith et al. 1994). Byrnes et al. (1985) found that CK, 
soreness, and myoglobin levels were lower following a second bout of downhill running 
when it was performed three and six weeks after the first bout but no difference when the 
bout was repeated at nine weeks. However, Nosaka et al. (2001) found indicators of the 
RBE six months following the initial bout of exercise.  
 
2.5.1 Possible mechanisms 
There are many theories as to why there is less damage to myofibrils during a 
second bout of an eccentric exercise.  McHugh (2003) attributed this protective 
adaptation to neuronal, mechanical, and cellular changes. The neuronal theory is based on 
more muscle fibers or a change in the type of muscle fibers being recruited. Due to 
straining the muscle tissue during the initial bout of eccentric exercise, more motor units 
may be activated during the second bout to disperse the stress over a greater area (Nosaka 
and Clarkson 1995, McHugh 2003). A second possibility could be that while mostly fast 
twitch fibers are recruited in the first bout, there may be a switch to slow-twitch fiber 
recruitment during the following bout (Warren et al. 2000, McHugh 2003). 
The theory of mechanical changes focuses on alterations in the cytoskeleton of the 
muscle such as connective tissue and desmin. Restructuring after damage from the first 
bout may lead to protection from the second bout. Lapier et al. (1995) found that rats with 
higher connective tissue mass in the hindlimb were less susceptible to contraction-
induced injury.  However, an increase in connective tissue could also lead to an increase 
in passive muscle stiffness resulting in less protection from an ensuing bout of exercise. 




exercise showed increased muscle soreness and decreased strength following isokinetic 
eccentric contractions of the hamstring. 
According to the cellular theory, the cell membrane strengthens in response to 
damage to prevent future disruptions (Clarkson and Tremblay 1988). Other possibilities 
are that the sarcomeres that were damaged were weak sarcomeres which are then 
replaced by stronger ones, or that the muscle fiber lengthens by adding more sarcomeres 
(McHugh et al. 1999, Newham 1988). Lastly, there may be changes to excitation 
contraction coupling after the initial bout resulting in less attenuation of strength after a 
repeated bout (Warren et al. 2000). 
 
 Estrogen 2.6
Estrogen is a group of 18-carbon hormones. The most common forms are 17β-
estradiol, estrone, and estriol.  Estrogens are produced in the ovaries as well as in the 
adrenal cortex. 17β-estradiol is the most abundant form in the premenopausal female 
after puberty (Johnson 2007). Estrogen has many roles in the body such as regulation of 
the menstrual cycle and development of secondary sex characteristics (Tortora and 
Derrickson 2009), and is currently being examined for its possible protective role against 
muscle damage and muscle soreness. 
Evidence from rat studies suggests that high estrogen levels offer protection 
against skeletal muscle damage. Bar et al. (1988) found that ovariectomized female rats 
had a significant increase in CK activity after exercise while control female rats did not. 
The study also showed that when male rats and female ovariectomized rats were treated 




their non-treated counterparts. Tiidus et al. (2001) found that ovariectomized rats 
supplemented with estrogen had decreased levels of CK, myeloperoxidase (MPO) which 
is generally expressed in neutrophils, and calpain-like activity one hour after exercise 
compared to their non-supplemented counterparts.  
When the sarcolemma is damaged following exercise, homeostasis of molecules 
and proteins can be disrupted in the muscle fiber. Sonobe et al. (2010) measured 
intracellular calcium levels in male, female, and ovariectomized female rats in response 
to eccentric contractions. They found a sex difference in the amount of calcium in the 
intracellular space following eccentric contractions with higher levels found in the male 
rats. They also found more hypercontracted muscle fibers in the male group than either 
female group. While no significant difference was found between intact female and 
ovariectomized rats, the ovariectomized females tended to have higher values of calcium 
and hypercontracted fibers than the non-ovariectomized female group. 
 
2.6.1 Possible Mechanisms 
The role of estrogen in reducing muscle damage is categorized into three main 
modes of action, i.e., acting as an antioxidant, a membrane stabilizer, or a regulator of 
gene expression (Kendall and Eston 2002).  It has been proposed that estrogen with its 
phenol ring may act as an antioxidant. The compounds resulting from estrogen 
breakdown may also have antioxidant capabilities similar to vitamin E (Sugioka et al. 
1987). As an antioxidant, estrogen could bind to ROS to decrease the amount of damage 
done to muscle cells. While ROS are important for certain gene regulators (e.g., TNF-




that estrogens were able to decrease the amount of lipid peroxidation in vitro.  Out of the 
three estrogens, estradiol appeared to have the greatest antioxidant properties. 
As a fat-soluble hormone, estrogen may interact with the cell membrane to 
decrease membrane fluidity.  In a study by Tiidus et al. (2001) ovariectomized rats were 
subjected to a running protocol that induced oxidative stress. Rats supplemented with 
estrogen showed decreased levels of CK and neutrophils compared to the non-
supplemented group. MPO and calpain-like activity were also lower in the estrogen 
group providing evidence that there is a membrane stabilization component. 
A third possible mechanism in support of estrogen’s involvement in mediating 
muscle damage is gene regulation. As previously mentioned, ROS is important for certain 
gene regulation, and estrogen’s potential as an antioxidant to bind ROS could impair gene 
regulation. The administration of estrogen one day prior to exercise in male rats did not 
result in any protective effects (no significant difference in CK); however, when estrogen 
was administered for three weeks prior to exercise there was a protective effect (Bar et al. 
1988). Due to the apparent delay in the response to estrogen administration before 
protection against muscle damage occurs, some gene regulation may need to take place 
prior to exercise.  
 
2.6.2 Estrogen Receptors 
Gene regulation via estrogen has been a focus of recent research. Estrogen acts as 
a ligand binding to a receptor which undergoes a conformational change to alter gene 
transcription. It was discovered that there were two variations of the receptor that 




(ERβ). What the receptors activate individually as well as how they interact with each 
other is still being studied. Recently, it has been shown that both ERα and ERβ are 
located on most of the nuclei in human skeletal muscle fibers in (Wiik et al. 2009). The 
role of estrogen receptors in skeletal muscle is still being elucidated. Recent studies 
indicate that the inflammatory and regeneration response following muscle damage may 
be influenced by estrogen receptor mediated pathways (Velders et al. 2012, Enns et al. 
2008). For example, proinflammatory markers were elevated in ovariectomized mice 
following muscle damage, whereas mice treated with ER ligands showed attenuated 
responses.  Three days after damage, mice treated with the ERβ agonist but not the ERα 
agonist ligand showed increases in markers of satellite cell activation compared to 
ovariectomized mice. ERβ knockout mice showed a decreased satellite cell activation 
response following muscle damage compared to both ERα knockout mice and wild type, 
providing evidence that estrogen may act through ERβ to alter the inflammatory response 
and muscle satellite cell activation (Velders et al. 2012). 
 
2.6.3 Findings in Females 
Data regarding estrogen’s protective effects are less conclusive in humans than in 
animal studies. Whereas there was a decreased CK response when male rats and 
ovariectomized female rats were given estrogen supplementation (Bar et al. 1988), 
studies using human subjects are more complicated due to large subject variability that 
must be taken into account. Moreover, the influence of exogenous vs endogenous 
estrogen on the responses to eccentric exercise in women remains unclear. Thompson et 




eccentric exercise. Subjects taking HC had lower 17β-estradiol levels compared to the 
control group (CG), and the CG showed more soreness in the quadriceps compared to HC 
users.  Soreness appeared to peak for both groups at 48 hours after exercise. While not 
statistically significant, it appeared CG had lower CK activity than the HC users.  The 
highest CK values for CG occurred on day three whereas HC users’ highest level was at 
day five. Higher estrogen levels do not appear to protect the muscle from increased 
soreness, but CK trends may be impacted by the higher levels. Carter et al. (2001) 
examined estrogen’s influence on markers of muscle damage following downhill running. 
The group with higher estrogen levels (HC users) showed significantly lower CK activity 
72 hours after eccentric exercise with no difference in muscle soreness.  Estrogen is also 
used for hormone therapy in postmenopausal women. Dieli-Conwright et al. (2009) 
found that postmenopausal women who were taking hormone therapy showed attenuated 
muscle protein activity (CK and LDH) after maximal eccentric knee extension exercises 
in contrast to a low estrogen CG which showed an increase in muscle protein activity.  
Stupka et al. (2000) examined differences in inflammation between males and 
females in response to eccentric contractions in an isolated leg muscle. The women (HC 
users) had significantly higher estrogen levels compared to the men. Contrary to previous 
reports (Bar et al. 1988), they found no statistical difference in CK between the men and 
women, perhaps due to the study being underpowered. It was found, however, that even 
though the level of muscle damage displayed in muscle biopsies was the same, markers 
of leukocytes (bcl-2-positive inflammatory cells (p<0.05) and leukocyte common antigen 
(p=0.052)) were higher in men compared to women. This provides evidence that there 




i.e., fewer neutrophils or macrophages may be recruited in women than men in response 
to muscle damage.  
There are limitations to the evidence for estrogen’s role in protecting against 
muscle damage in humans such as HC use and differences in testing techniques. Another 
area that lacks clarity is the role of estrogen in the RBE. If estrogen attenuates muscle 
damage from the first bout of eccentric exercise it is unclear if markers of the RBE will 
be altered.  
 Summary 2.7
Unaccustomed eccentric exercise results in muscle damage, muscle soreness, 
decreased muscular strength, inflammation, and an acute immune response. Estrogen has 
been shown in animal studies to attenuate these responses while results of human studies 
have been mixed. The RBE also attenuates these markers, but it is unknown how these 




CHAPTER 3. MATERIALS AND METHODS 
 Participants 3.1
Participants for this study were 13 moderately active premenopausal women 
between 18 and 35 years of age. They completed questionnaires detailing menstrual cycle 
history and daily activity level (Paffenbarger 1997) to assess inclusion/exclusion 
qualifications. Only women who had regular menstrual cycles (no missed periods for the 
last 6 months), using HC, were moderately active [VO2 max between 36 to 47 ml/kg/min 
(Heyward 2006) and not engaged in intense exercise for more than one hour a day three 
times a week] were included. Participants were excluded if they were irregularly 
menstruating, ovariectomized, smokers, taking cardiac or anti-inflammatory medications, 
had any musculoskeletal limitations, or had ovarian or breast cancer. 
All procedures were approved by the Institutional Review Board (Protocol 
#1308013928). Participants provided written consent prior to participation in the study. 
 
 VO2 max Testing Protocol 3.2
A progressive intensity, continuous VO2 max test protocol on a treadmill was 
used to determine if women met the abovementioned criterion for being moderately 
active. Women walked on the treadmill at a pace of 3.5 mph at 0% incline for three 




increased every two minutes by 1 mph until reaching 7 mph, after which the treadmill 
grade increased by 2% every two minutes. Criteria for determining if a subject reached 
her VO2 max included meeting two of the following criteria: RER ≥1.15, heart rate at or 
near the age predicted maximum, voluntary termination, and < 150 ml/min increase in 
VO2 with an increase in workload. 
 
 Experimental Design 3.3
After qualifying for the study, participants were divided into two groups:  a low 
estrogen group (LE; n=7) and a high estrogen group (HE; n=6). Women during their third 
week of hormone use were classified as LE (due to endogenous estrogen concentration 
being suppressed during this part of the menstrual cycle) and HC users during their 
placebo week were classified as HE. They subsequently completed two 40-min downhill 
running trials on a treadmill separated by approximately one month. Exercise intensity 
was 65-70% VO2 max at a -10% grade. 
 
 Experimental Trials 3.4
Women were asked to fast overnight and refrain from strenuous activities for two 
days prior to the downhill runs. They were given a three minute warm-up consisting of 
walking on the treadmill at a speed of 3.5 mph. Speed was then incrementally increased 
to a target value (based on the VO2 max test) that elicited 65-70% of the VO2 max. The 
speed for the second downhill was identical to that of the first run. The two trials were 




phase of their menstrual cycle. Measurements recorded during the treadmill runs included 
rating of perceived exertion (RPE), HR, and VO2.  
 
 Measurements 3.5
Muscle soreness, leg pressure tolerance, leg circumference, peak muscle torque, 
17 β-estradiol and creatine kinase activity measurements were recorded at various time 
points before and after the trials as shown in Table 1.  
 
Table 1. Timeline of measurements.  
 Pre-exercise 0hrs 24hrs 48hrs 72hrs 
Soreness  X X X X 
Circumference X  X X X 
Pressure 
Tolerance X  X X X 
Estradiol X     
CK X  X X X 
Peak Torque X    X 
 
Duplicate circumference measurements were taken on the right leg at mid-thigh 
and calf prior to each trial and at 24, 48, and 72hrs post exercise using a tape measure. If 
the two readings were more than 5mm apart then a third measurement was performed. 
For thigh circumference, women placed their knee on a bench with the leg at a 90 degree 
angle. The measurement was taken midway between the inguinal crease and the proximal 




ground and approximately 20 cm apart. The measurement was taken at the point of 
maximal circumference between the knee and the ankle. The distance from the medial 
malleolus to the area of measurement on the calf was recorded for repeated 
measurements. 
Muscle soreness of the front thigh, calf, and shin was assessed using a subjective 
rating scale ranging from 0-6 (Rodenburg et al. 1993) immediately after exercise and at 
24, 48, and 72hrs post exercise. An algometer (JTECH Medical Commander Algometer, 
Midvale, UT) was used to determine pressure tolerance prior to the trials and at 24, 48, 
and 72hrs post exercise. Pressure was applied on the right front thigh, shin (1cm lateral to 
the tibia) and calf at the location of the circumference measurements at a rate of 2 lb/sec 
using a 1 cm2 probe.  Subjects were asked to say “yes” when they felt pain. Subjects were 
supine for front thigh and shin measurements and prone for calf measurements. Each area 
was measured once in rotation before a repeated measurement was taken. 
Peak isometric torque production of the right leg during leg extension and ankle 
dorsiflexion was measured using a Humac Cybex (Henley Healthcare, Sugar Land, TX) 
machine. Participants performed three sets of five repetitions (30 sec rest between sets) 
during which they were asked to exert as much force as possible against the resistance. 
Leg extension testing was performed at a speed of 60deg/sec with the subject in a sitting 
position. Ankle dorsiflexion was performed at a speed of 30deg/sec with the subject in a 
supine position with her upper leg perpendicular and lower leg about parallel to the floor.  





 Blood Sampling and Preparation 3.6
A 4 ml blood sample was drawn into serum separator tubes from an antecubital 
vein immediately before the first (DH1) and second (DH2) downhill runs, and 2 ml blood 
samples were taken for the post exercise samples. Blood was allowed to clot for 30 min 
following five inversions of the tubes then centrifuged for 10 min at 1000-1300g. Serum 
was collected and stored at -80 °C until analyzed for CK and 17β-estradiol.   
 
 Analyses 3.7
3.7.1 CK activity 
Blood samples were analyzed for CK activity using an enzymatic assay according 
to the manufacturer’s protocol (Pointe Scientific, Inc. Lincoln Park, MI).  50µl of serum 
was pipetted into a cuvette containing 1ml of pre-warmed reagent. The cuvette was 
inverted three times and measured two minutes later using a spectrophotometer 
(SpectraMax M2e, Molecular Devices, LLC Sunnyvale, CA) at 37°C.  The average 
change in absorption per minute (ΔAbs/min) was record and used to calculate CK activity 
(U/L) by using the equation (ΔAbs/min x 1.05)/(0.00622 x 0.05). 
 
3.7.2 Estrogen (17 β-estradiol) 
Estrogen concentrations, specifically 17 β-estradiol, were measured using an 
enzyme-linked immunosorbent assay (ELISA). Following the manufacturer’s protocol 
(ALPCO, Salem, NH) serum samples were analyzed in duplicate. A 4-parameter curve 
was calculated (SoftMax Pro 5.4 Molecular Devices, LLC. Sunnyvale, CA) and used to 




 Statistical Analysis 3.8
Results are shown as the mean +SE.  Subject characteristics were analyzed using 
t-tests. All other data were analyzed using a group (HE and LE) x run (DH1 and DH2) x 
time (pre, and 0, 24, 48, and 72hrs postexercise) mixed model ANOVA. A Tukey post-




CHAPTER 4. RESULTS 
Subject characteristics are summarized in Table 2. There was no significant 
difference between the groups for VO2 max, height, body mass, or age. A dependent t-
test showed that estradiol did not differ between DH1 and DH2, so the values were 
averaged across the runs.  Although not statistically significant, estradiol concentration in 
HE tended to be higher than in LE (P=0.07).  
 







Mass (kg) Age 
(years) 
High Group  75.1 ± 11.8 
(34-107) 
40.4 ± 1.7 
(37-46) 
165.8 ± 1.7 
(160-170) 
67.0 ± 3.1 
(59-78) 
23.7 ± 1.9 
(20-29) 
Low group  45.2 ± 9.7 
(13-94) 
41.2 ± 1.4 
(37-46) 
166.3 ± 1.8 
(165-170) 
65.2 ± 6.7 
(50-102) 
22.0 ± 0.9 
(18-25) 





 Pressure Tolerance 4.1
Pressure tolerance for the front thigh is shown in Figure 1. Although there was no 
significant run x time x group interaction, there was a run effect. Pressure tolerance 
following DH1 (9.2 ± 0.8 lb/cm2) was lower than DH2 (10.1 ± 0.8 lb/cm2) (P = 0.009) 
 
 
Figure 1. Pressure tolerance of the front thigh for the first (DH1) and second (DH2) downhill runs. Values 
are X±SEM. H=high estrogen group; L=low estrogen group. Pressure tolerance was lower for DH1 than 
DH2 (P < 0.01). 
Pressure tolerance for the shin is shown in Figure 2. There were no significant 









































Figure 2. Pressure tolerance of the shin for the first (DH1) and second (DH2) downhill runs. Values are 
X±SEM.  H=high estrogen group; L=low estrogen group. 
Pressure tolerance for the calf is shown in Figure 3. A run effect was observed 
such that pressure tolerance was lower following DH1 (9.1 ± 0.7 lb/cm2) than DH2 (10.0 
± 0.7 lb/cm2) (P = 0.02).  
 
Figure 3. Pressure tolerance of the calf for the first (DH1) and second (DH2) downhill runs. Values are 
X±SEM. H=high estrogen group; L=low estrogen group. Pressure tolerance was lower for DH1 than DH2 





































































 Perceived Soreness 4.2
Muscle soreness of the front thigh is shown in figure 4. A significant run effect 
was observed.  Front thigh muscle soreness was lower after DH2 (2.5 ± 0.2) than DH1 
(3.2 ± 0.2) (P = 0.05). 
 
 
Figure 4. Perceived soreness of the front thigh for the first (DH1) and second (DH2) downhill runs. Values 
are X±SEM. H=high estrogen group; L=low estrogen group. Soreness was higher for DH1 than DH2 (P = 
0.05). 
Muscle soreness of the shin is shown in figure 5.  There was a significant group x 
time interaction (P = 0.05).  LE had increased shin soreness at 24 (3.0 ±0.4) (P < 0.001) 
and 48 hr (2.6 ± 0.4) (P < 0.001) compared to 0 hr (1.0 ± 0.4) and 72 hr (1.5 ± 0.4) (24 hr: 




































Figure 5. Perceived soreness of the shin for the first (DH1) and second (DH2) downhill runs. Values are 
X±SEM. H=High estrogen Group; L=low estrogen group. α Higher than 0 hr in L. β Higher than 72 hr in L. 
Muscle soreness of the calf is shown in Figure 6.  There were no significant 
interactions or main effects.  
 
 
Figure 6. Perceived soreness of the calf for the first (DH1) and second (DH2) downhill runs. Values are 



































































 CK Activity 4.3
CK activity is shown in Figure 7. A significant run x time interaction was 
observed. Compared to pre (76.1 ± 44.8 U/L), CK activity following DH1 was higher at 
24 hr (433.5 ± 44.8 U/L) (P < 0.001), 48 hr (224.4 ± 44.8 U/L) (P = 0.04), and 72 hr 
(230.8 ± 44.8 U/L) (P = 0.03), with 24 hr also higher than 48 hr (P < 0.001) and 72 hr (P 
< 0.01). CK activity at 24 hr following DH2 (202.4 ± 44.8 U/L) was lower than at 24 hr 
following DH1 (P < 0.001). 
 
 
Figure 7. Creatine Kinase(CK) activity for the first (DH1) and second (DH2) downhill runs. Values are 
X±SEM. H=high estrogen group; L=low estrogen group. * Higher than 0 hr in DH1. # Lower than 24 hr 
DH1. 
 Muscle Circumference 4.4
Circumference measurements of the thigh and calf are shown in Figure 8 and 9, 

































Figure 8. Circumference of the thigh for the first (DH1) and second (DH2) downhill runs. Values are 
X±SEM. H=high estrogen group; L=low estrogen group. 
 
Figure 9. Circumference of the calf for the first (DH1) and second (DH2) downhill runs. Values are 






























































 Peak Torque 4.5
Peak torque for knee extension and ankle dorsiflexion is shown in Figures 10 and 
11, respectively.  No significant changes, main effects, or interactions were observed. 
 
 
Figure 10. Peak torque for knee extension for the first (DH1) and second (DH2) downhill runs. Values are 
X±SEM. High=high estrogen group; Low=low estrogen group. 
 
Figure 11. Peak torque for ankle dorsiflexion for the first (DH1) and second (DH2) downhill runs. Values 
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CHAPTER 5.  DISCUSSION 
Increased tenderness (Eston et al. 2000) and muscle soreness (He et al.  2015), 
which are reflective of exercise-induced muscle damage, generally occur following the 
first exposure to an eccentrically-biased exercise such as downhill running.  In the present 
study, increased muscle soreness and CK activity were observed following the initial 
bout of exercise. Hence, the exercise protocol was successful in inducing markers of 
muscle damage in our women participants.  
Because it has been suggested that estrogen may influence muscle damage and 
recovery through its properties as a membrane stabilizer, antioxidant, or gene regulator 
(Kendall and Eston 2002), the first aim of this study was to determine if estrogen levels at 
the time of exercise influenced the ensuing muscle soreness and CK response following 
unaccustomed eccentric exercise.  In the present study, women with lower estrogen 
showed greater perceived muscle soreness in the shin than women with higher estrogen, 
providing partial support for the hypothesis. Thus, the higher concentration of estrogen in 
HE may have attenuated the muscle soreness response following the first exercise bout. 
Estrogen, as a fat-soluble hormone, may interact with the cell membrane to stabilize the 
membrane by decreasing fluidity and lipid peroxidation and therefore reduce damage 






Increased plasma/serum CK activity is observed following muscle-disrupting 
activities (He et al. 2015, Eston et al. 2000).  In the present study CK activity 
increased following the initial bout of exercise, but no differences were detected 
between the groups. These results are not consistent with previous animal (Bar et al. 
1988, Tiidus et al. 2001) and human (Carter et al. 2001) studies where attenuated CK 
responses in higher estrogen groups were reported.  Due to CK activity’s variability 
between subjects, the sample size of this study may not have been large enough to 
detect a significant difference as was the case for Stupka et al. (2000).  
Decreased muscle performance is an indirect marker of muscle damage 
(Radaelli et al. 2014, Jakeman and Eston 2013).  No changes in peak torque for knee 
extension or ankle dorsiflexion were observed in the present study. Although 
decreased force production is known to persist for as long as three days following 
downhill running (Eston et al. 2000), it is possible that if our women experienced any 
changes in peak torque, recovery may had occurred such that changes in peak torque 
were not detected at 72 hr postexercise when these measurements were made. 
Because all of our participants were female, and most likely had higher estrogen 
concentrations than males, it may be that recovery occurred sooner than participants 
in the study by Eston et al (2000) who were predominately men.  
An inflammatory response occurs following muscle damage, and often results 
in swelling of the affected area. This acute-phase immune response is initiated in 
order to clean up debris, but the process itself may cause more damage through the 
release of ROS. Estrogen’s antioxidant properties may help neutralize ROS, thus 





Increases in circumference have been shown following various anaerobic isolated 
muscle eccentric exercises (Radaelli et al. 2014, Nosaka et al. 2002, Savage and 
Clarkson 2002), but not after aerobic bench stepping exercises (Thompson et al. 
1997). It is possible that swelling from muscle damage following aerobic exercise (in 
contrast to isolated muscle group exercise) may be dispersed over a larger area such 
that circumference measurements are not adequately sensitive to detect significant 
changes and may be why no significant change in circumference measurements was 
noted in the present study.  
The RBE is characterized by attenuated markers of muscle damage following 
a second bout of the same exercise (Byrnes et al. 1985).  As evidenced by Chen 
(2006), muscle damage following the initial bout must be substantial enough to 
initiate an adaptive response so that the RBE becomes evident. While, mechanisms of 
the RBE are not thoroughly understood, it has been theorized that changes in muscle 
fiber recruitment (number or type), muscle cytoskeleton, and/or the muscle cell 
membrane may be involved in the RBE (McHugh 2003).  Estrogen receptor mediated 
pathways may influence the inflammatory and regeneration response (Velders et al. 
2012, Enns et al. 2008). It is possible that higher estrogen levels may enhance the 
recovery process through increased activity of certain pathways, such as satellite cell 
activation (Velders et al. 2012).  The second aim of this study was to determine if 
estrogen levels at the time of exercise would alter markers of the RBE. In general, 
pressure tolerance, muscle soreness, and CK activity were attenuated following the 
second downhill run, indicating that the RBE was evident in our women participants. 





between the groups. To our knowledge, this is the first study to examine the effect of 
estrogen on the RBE in women, thus estrogen’s role in the recovery process following 
muscle damage in women needs further investigation.  
There are several limitations of this study that could have impacted the 
outcomes.  The difference in estrogen concentration between the two groups of 
women in this study was not as large as in several previous reports (Thompson et al. 
1997, Carter et al. 2001).  Therefore, a different sampling technique that would have 
resulted in a larger difference in estrogen between our groups may have increased our 
ability to detect changes in some of the markers of muscle damage. Armstrong (1990) 
noted that soreness tended to localize in the distal end of the muscle. Whether this is 
due to most of the damage occurring in this area or due to pain receptors being 
localized there, examining pressure tolerance and circumference in the distal end of 
the muscle may have led to a more robust response. Finally, increasing our sample 
size would have provided more statistical power, enhancing our ability to detect an 
estrogen effect if there indeed is one. 
In conclusion, it was hypothesized that markers of muscle damage in women 
with higher estrogen concentrations would be attenuated following both an initial 
exercise bout and a second bout compared to women with lower estrogen.  Results 
provide evidence that higher estrogen levels at the time of exercise may mitigate 
markers of muscle damage following an initial bout of exercise, but higher estrogen 






 Recommendations for Future Research 5.1
It is unknown what impact there would be on markers of the RBE if the first 
bout of muscle damaging exercise is performed when estrogen concentration is high 
and the second bout is performed when it is low and vice versa. Future studies 
alternating estrogen levels between bouts of exercise would increase our 
understanding on the relationship of estrogen levels and the RBE.  
Many of the studies examining estrogen’s role in muscle protection have 
compared HC users to nonusers (Thompson et al. 1997, Cater et al. 2001, Savage and 
Clarkson 2002). In order to remove the factor of exogenous estrogen and 
progesterone, future research using only non-HC users should be explored in order to 
determine if the results would support the findings of this study. 
While the exact mechanism by which estrogen protects the muscle from 
damage is unknown, previous research in rats (Bar et al. 1988) showed that some time 
was needed for estrogen to have a protective effect, suggesting gene regulation may 
first need to occur. Research exploring the role of estrogen receptors on the muscle 
cell nucleus indicated that estrogen receptor-β may play a significant role in 
protection from muscle damage (Velders et al. 2012). Future research focusing on this 
receptor and its subsequent downstream signaling may elucidate the mechanisms 
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Appendix A  Menstrual, and Physical Activity History  
Medical History Survey 
 
Name: ______________________ Local phone no: ________________________ 
Local address: ___________________________________________________________ 
Birth date: ___________________ Age: _______________ Sex: _________                                           
Weight: ________________ Height: _________________ 
 
1. Have you ever been diagnosed as having: (check all that apply) 
 Never In past Presently 
Heart Disease _________ _________ _________ 
Rheumatic Fever _________ _________ _________ 
High blood Pressure _________ _________ _________ 
Other vascular disorders _________ _________ _________ 
Diabetes _________ _________ _________ 
Kidney Disease _________ _________ _________ 
Asthma _________ _________ _________ 
Allergies _________ _________ _________ 
Chronic bronchitis _________ _________ _________ 
Other respiratory illness _________ _________ _________ 
High serum lipids _________ _________ _________ 
Osteoporosis  _________ _________ _________ 
Other bone disease _________ _________ _________ 
Neuromuscular-skeletal disease _________ _________ _________ 
 
















4. Please list any and all medications that you are presently taking: 
Medication Dosage Dosage per day 
_____________ _____________ _____________ 
_____________ _____________ _____________ 
 
5. Do you smoke? _________       Packs per day?_______________ 
 
6. Describe your present training program (the activity, amount/day, days/week, and 
length of time you have been training at this level) 
Activity Minutes/Day Day/week Weeks of training 
_____________ _____________ _____________ _____________ 
_____________ _____________ _____________ _____________ 







Menstrual Cycle History Questionnaire 
Name: ____________________ 





1. In recent months, what is the usual length of time from the beginning of your period to 
the beginning of your next period? 
     < 21 days _____ 
21 – 23 days _____ 
24 – 26 days _____ 
27 – 29 days _____ 
30 – 32 days______ 
33 – 35 days______ 
    > 35 days ______ 
 
2. A. Disregarding the first 18 months immediately following your first period have you 





   B. If answer is yes, approximately how old were you when missing a menstrual 
cycle?________________ 
 
   C. When was the last time a menstrual cycle was missed? (How many years/months       
ago?)___________________ 
 
   D. How long did this irregularity continue? _________________________ 
 
 
3. How many periods have you had in the past year? 
 
3 or less ____ 
4 – 7      ____ 
8 – 12    ____ 
 
4. How many periods have you had in the last 6 months? 
 
1 or none ____ 
2 – 4 _____ 






5. A. Have you ever used hormonal contraceptives? 
 
  Yes ___ 
  No  ___ 
 
 
   B. If yes, when was the last time you used them? 
 
Presently ____ 
  Within the last 6 months____ 
  More than 6 months ago____ 
 
6. At what time during each month does you menstrual cycle typically begin? 
  
Approximately the ____ day of the month 
 
7. What to you weigh at present?  _____ pounds 
 






Paffenbarger Physical Activity Questionnaire 
 
1. How many city blocks or their equivalent do you normally walk each day? 
_______ Blocks/day (let 12 blocks=1mile) 
 
 
2. What is your usual pace of walking? (please check one) 
a.____ Casual or strolling (less than 2 mph)                  b. ____Average or normal (2 to 3 
mph) 








4. List any sports or recreation you have actively participated in during the past year. 







Average Time/Episode Years 
Participation Hours  Minutes 
a.     
b.     
c.     
d.     
e.     
f.     
 
 
5. Which of these statements best expresses your view? (Please check one.) 
a. ___I take enough exercise to keep healthy 
b. ___ I ought to take more exercise  
c. ___Don’t know 
 
 
6. At least once a week, do you engage in regular activity akin to brisk walking, jogging, 
bicycling, swimming, etc. long enough to work up a sweat, get your heat thumping, or get 
out of breath? 
___No Why not?____________________________ 








7. When you are exercising in your usual fashion, how would you rate your level of 
exertion (degree of effort)? (please circle one number.) 
 































8. On a usual weekday and a weekend day, how much time do your spend on the 
following activity? Total for each day should add up to 24 hours. 
 Usually Weekday 
Hours/Day 
Usual Weekend Day 
Hours/Day 
a. Vigorous activity (digging in the 
garden, strenuous 
sports, jogging, aerobic dancing, 
sustained swimming, 




b. Moderate activity (housework, light 
sports, regular 
walking, golf, yard work, lawn mowing, 
painting, 
repairing, light carpentry, ballroom 
dancing, bicycling 
on level ground, etc.) 
 
  
c. Light activity (office work, driving car, 
strolling, 




d. Sitting activity (eating, reading, desk 
work, 
watching TV, listening to radio, etc.) 
 
  








Appendix B Delayed Onset of Muscle Soreness Questionnaire 
Delayed onset of muscle soreness questionnaire 
Subject:       Test: 
Rate of Scale (1-6) 
0=complete absence of soreness 
2=right pain felt only on palpation 
4=moderate pain, some stiffness and / or weakness, especially during movement 
6=severe pain that limits the range of motion 
 
 
Immediately after exercise 
Buttocks ( 0              1              2              3              4              5              6 ) 
Front of thigh ( 0              1              2              3              4              5              6 ) 
Back of thigh ( 0              1              2              3              4              5              6 ) 
Shin ( 0              1              2              3              4              5              6 ) 









24 hours after exercise 
Buttocks ( 0              1              2              3              4              5              6 ) 
Front of thigh ( 0              1              2              3              4              5              6 ) 
Back of thigh ( 0              1              2              3              4              5              6 ) 
Shin ( 0              1              2              3              4              5              6 ) 
Calf ( 0              1              2              3              4              5              6 ) 
 
48hours after exercise 
Buttocks ( 0              1              2              3              4              5              6 ) 
Front of thigh ( 0              1              2              3              4              5              6 ) 
Back of thigh ( 0              1              2              3              4              5              6 ) 
Shin ( 0              1              2              3              4              5              6 ) 
Calf ( 0              1              2              3              4              5              6 ) 
 
72 hours after exercise 
Buttocks ( 0              1              2              3              4              5              6 ) 
Front of thigh ( 0              1              2              3              4              5              6 ) 
Back of thigh ( 0              1              2              3              4              5              6 ) 
Shin ( 0              1              2              3              4              5              6 ) 






Appendix C Informed Consent 
RESEARCH PARTICIPANT CONSENT FORM 
Estrogen and Muscle Soreness 
Dr. Darlene Sedlock 
Purdue University 
Department of Health & Kinesiology 
 
Purpose of Research 
After you exercise in a way you are not accustomed to, your muscles often 
become sore a day or two later and then get better within the next few days.  The soreness 
is a result of the body’s response to microdamage in the muscles from the exercise.  If 
you then do that same exercise again, after this second bout you won’t be nearly as sore if 
at all.  Research has shown that women tend to experience less muscle soreness than men 
after the first bout of an unaccustomed exercise. This is thought to be due to the different 
levels of estrogen between men and women.  However, estrogen’s effect on muscle 
soreness following a second bout of exercise is unknown. Thus, we are doing this study 
to see if estrogen levels at the time of doing some unaccustomed exercise (in this case the 
exercise is running downhill) will reduce muscle soreness and markers of muscle damage 
following both bouts of exercise.  You are being asked to participate because you are a 
regular exerciser who may occasionally experience muscle soreness. 
 
Specific Procedures  
You will first be asked to complete some preliminary requirements to see if you 
qualify for the study.  These requirements include completing some questionnaires 
related to your menstrual, medical, and health histories, and physical activity 
participation.  We will measure your height, weight, resting heart rate and resting blood 
pressure, and assess your aerobic fitness with an exercise test (VO2max).  For the 
exercise test, you will be wearing a mouthpiece attached to a breathing valve which lets 
you breathe in room air while your exhaled air is directed to a machine that performs 
some measurements on the air.  We will also monitor your heart rate by having you put a 
strap around your chest.  The exercise will be performed on a treadmill.  Initial speed will 
be 3.5 mph. Speed will increase by 1 mph every three minutes up to 6.5 mph, after which 
the grade will increase by 2% every two minutes without a change of speed.  You will be 
asked to give a maximum effort on this test.  If you do not qualify for the study based on 
these preliminary tests, you will be involuntarily withdrawn from the study. 
If you qualify for the study based on the questionnaires and exercise test, you will 
be asked to perform a 40 minute downhill (-10%) run on the treadmill at a specific time 






your menstrual cycle) you will do the same run.  For these exercise trials you will have to 
fast overnight and refrain from intense exercise for 2 days prior to the runs.  The trials 
will be in the morning. 
When you report to the lab, your height and weight will be measured. This will be 
followed by a 20 min rest after which we will take some blood (~ 1 tablespoon) from an 
arm vein, measure the circumference of your thigh and calf, test your leg strength, and 
check for any leg muscle soreness by using an instrument that applies pressure to your 
leg muscles (similar to poking a finger in the muscle).  Then we will attach the same 
heart rate chest strap and device for the mouthpiece as we did during the VO2max test 
and begin the exercise:  after a 3 minute warm-up you will run downhill for 40 min.  In 
the morning during the next three days (at 24, 48, and 72 hr after the exercise) you will 
come to the lab and rate any muscle soreness using a 0-6 rating scale, have another blood 
sample taken (~ 1 teaspoon) and have your leg circumference and muscle soreness 
(pressure) measurements taken again.  During the 72 hr postexercise visit we will also 
measure your leg strength once more. 
Approximately four weeks after the first downhill run you will perform the 
second downhill run.  The exercise, blood sampling procedures, muscle soreness ratings, 
leg circumference, leg strength, and leg soreness (pressure) measurements for this run 
will be done in the same way as for the previous run.  
 
Duration of Participation 
The preliminary requirements will take a total of approximately one hour, i.e, 
about 15 min for questionnaires and about 45 min for the exercise test.  Each exercise 
session will take approximately 1.25 - 1.5 hours.  The blood draws and other 
measurements at 24, 48 and 72 hr after exercise will take ~15 min each.  Muscle soreness 
ratings will take a few minutes each. Therefore, the total time commitment will be about 
5.5 hours over the approximately 9 week study duration. 
 
Risks  
Risks associated with this study are mainly associated with the exercises and with 
blood sampling. Because you will be engaging in a VO2max test (aerobic fitness) as well 
as 2 treadmill runs you will be stressing your cardiovascular system throughout the 
exercise periods. Thus, there exists the possibility of risks and discomfort during the 
exercise tests such as: abnormal blood pressure, fainting, irregular, fast or slow heart 
rhythm, and in rare instances heart attack, stroke or death.  However, you must meet 
specific criteria to participate in the study, i.e., you are already a regular exerciser.  In 
addition you will complete a health history questionnaire prior to the study to ensure that 
you don't have any risk factors associated with cardiovascular disease. There is also a 
slight risk of losing your balance when running downhill.  To minimize this, your 
exercise will be monitored and you will be given verbal instructions to move forward, 
backward, or to the center of the treadmill if necessary.  Someone involved with the study 
will also be by the treadmill while you are running.  You will probably experience some 
degree of muscle soreness following the downhill run.  Additionally, it is possible that 






promote your safety by carefully monitoring the equipment, your measurements, and you 
during all tests.  Test technicians are trained in exercise testing, are CPR and AED 
certified, and knowledgeable in obtaining Emergency Medical Services.  Emergency 
equipment is in close proximity to the laboratory.  
You may experience some discomfort (pain) when having your blood drawn.  
There is also a risk of fainting, and a remote risk of infection and/or bruising when 
sampling blood.  These risks will be minimized by having your blood drawn by an 
individual trained in these procedures.   
Finally, there is a risk of breach of confidentiality.  This risk will be minimized by 
using procedures outlined below in the confidentiality section. 
 
Benefits 
There are no anticipated direct benefits to you by participating in the study. 
However, you will receive information about your fitness level, estrogen levels and 
cardiovascular system responses to exercise.  Additionally, as a regular exerciser who 
might occasionally experience exercise-induced muscle soreness, you may benefit from 
information derived from this study. 
Please feel free to consult with your physician for interpretation of any 
information you receive from participating in this study. 
 
Compensation  
You will receive $50 for participation in this study upon completion of the 
requirements.  There is no compensation for partial completion of the requirements. 
 
Injury or Illness 
Purdue University will not provide medical treatment or financial compensation if 
you are injured or become ill as a result of participating in this research project.  This 




All of your data will be coded and not associated with your name. Data will be 
kept until three years after the last presentation or publication of the results, and will be 
located in a file cabinet in a locked room in Lambert Bldg that is available only to staff 
associated with the study. The code linking your name with your data will be destroyed at 
the same time as the other data.  Electronic records will be kept on a password-protected 
drive and are accessible only by staff associated with the study.  You may have access to 
your data upon request.  Blood samples will be kept for a maximum of two years from 
the completion of the study. 
The project's research records may be reviewed by departments at Purdue 









Voluntary Nature of Participation 
You do not have to participate in this research project.  If you agree to participate 
you can withdraw your participation at any time without penalty. 
 
Contact Information 
If you have any questions about this research project, you can contact Dr. Darlene 
Sedlock (765-494-3184, sedlock@purdue.edu)  or Jennifer Hockemeyer (260-385-4428, 
kruseja@purdue.edu).  If you have concerns about the treatment of research participants, 
you can contact the Institutional Review Board at Purdue University, Ernest C. Young 
Hall, Room 1032, 155 S. Grant St., West Lafayette, IN 47907-2114. The phone number 
for the Board is (765) 494-5942.  The email address is irb@purdue.edu. 
 
 
Documentation of Informed Consent: 
 
I have had the opportunity to read this consent form and have the research study 
explained.  I have had the opportunity to ask questions about the research project and my 
questions have been answered.  I am prepared to participate in the research project 
described above.  I will receive a copy of this consent form after I sign it.   
 
___________________________________________                _____________________ 
              Participant’s Signature                                                                             Date 
  
__________________________________________                           
              Participant’s Name 
 
__________________________________________                  _____________________ 








Appendix D Raw Data 
Raw data set 1: Estradiol (pg/ml) 
High Estrogen Group (H) 
Sub ID D1PRE D2PRE 
Sub 1 59.68 45.15 
Sub 6 195.75 15.54 
Sub 9 45.05 22.97 
Sub 10 49.23 99.74 
Sub 18 112.56 102.43 
Sub 22 73.02 80.23 
   Low Estrogen Group (L) 
Sub ID D1PRE D2PRE 
Sub 3 21.27 41.95 
Sub 5 49.32 32.59 
Sub 15 12.46 13.80 
Sub 16 84.91 103.52 
Sub 19 33.43 42.23 
Sub 20 49.39 69.01 





Raw data set 2: Front thigh pressure tolerance (lb/cm2) 
High Estrogen Group (H) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 1 9.9 11.8 10.1 9.8 11.1 13.3 
 
13.0 
Sub 6 10.8 8.3 9.1 8.1 8.4 7.9 8.9 9.5 
Sub 9 16.9 11.4 13.0 14.7 17.8 13.2 17.2 17.2 
Sub 10 15.1 12.8 12.4 12.8 13.1 11.3 12.9 12.8 
Sub 18 10.5 8.7 7.4 8.4 10.3 10.2 10.1 10.8 
Sub 22 5.8 4.8 5.9 5.6 6.7 4.9 4.9 5.9 
         Low Estrogen Group (L) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 3 10.8 9.7 10.3 9.7 12.4 12.3 12.3 10.3 
Sub 5 8.3 7.1 5.9 6.1 10.2 8.4 8.5 8.5 
Sub 15 7.6 5.0 4.9 5.1 8.6 6.1 6.3 6.1 
Sub 16 10.1 10.7 10.2 12.9 15.4 9.3 9.6 11.7 
Sub 19 7.4 4.5 4.6 5.4 5.6 5.8 5.8 6.3 
Sub 20 9.5 8.7 8.3 7.5 9.1 8.4 8.5 10.2 






Raw data set 3: Shin pressure tolerance (lb/cm2) 
High Estrogen Group (H) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 1 11.8 12.1 10.9 11.0 12.5 12.1 
 
12.8 
Sub 6 16.0 11.9 9.4 9.2 12.3 12.4 10.8 11.9 
Sub 9 19.8 13.1 13.5 16.3 22.0 17.7 22.8 21.7 
Sub 10 15.2 15.2 11.7 14.9 13.1 13.5 11.8 14.5 
Sub 18 11.8 8.5 9.5 10.5 11.3 9.5 12.5 13.0 
Sub 22 10.0 6.1 7.3 7.9 8.4 6.9 5.5 7.4 
         Low Estrogen Group (L) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 3 10.7 9.8 10.5 13.1 21.0 11.9 17.1 19.7 
Sub 5 9.7 7.1 7.4 8.1 11.6 9.1 11.3 9.0 
Sub 15 10.9 8.9 14.2 10.7 11.5 11.0 12.4 9.3 
Sub 16 14.5 9.4 11.7 13.9 14.8 7.9 9.6 12.2 
Sub 19 10.8 7.0 6.0 6.1 7.6 6.9 7.4 8.4 
Sub 20 12.7 7.9 8.7 9.4 10.7 10.2 9.2 12.6 






Raw data set 4: Calf pressure tolerance (lb/cm2) 
High Estrogen Group (H) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 1 7.0 8.0 7.9 7.1 8.6 8.0 
 
9.5 
Sub 6 9.9 8.7 8.1 8.8 8.7 8.4 7.3 8.7 
Sub 9 12.7 11.7 12.6 14.1 14.9 13.3 16.2 18.5 
Sub 10 12.6 11.5 11.8 12.5 9.5 10.8 12.1 13.3 
Sub 18 9.8 8.7 8.4 8.4 10.8 10.5 9.9 9.4 
Sub 22 7.1 6.2 6.1 6.1 7.7 6.9 5.6 6.5 
         Low Estrogen Group (L) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 3 9.3 8.9 8.3 9.4 14.2 11.0 10.0 11.5 
Sub 5 7.9 6.7 4.9 6.0 8.6 7.5 7.7 7.9 
Sub 15 8.1 7.8 6.0 8.8 9.0 8.7 8.9 7.7 
Sub 16 15.8 9.1 11.9 13.5 14.4 10.1 12.2 11.4 
Sub 19 8.5 5.4 5.7 6.0 7.6 6.7 6.7 7.0 
Sub 20 10.8 10.3 10.0 11.6 11.3 11.7 10.7 11.9 






Raw data set 5: Front thigh muscle soreness score 
High Estrogen Group (H) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 1 4 5 4 3 4 3 
 
2 
Sub 6 3 5 3 1 2 4 0 0 
Sub 9 4 4 2 2 3 3 4 2 
Sub 10 2 4 3 2 2 2 3 3 
Sub 18 3 5 6 4 0 2 3 1 
Sub 22 2 4 3 2 1 4 4 2 
         Low Estrogen Group (L) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 3 3 5 5 2 1 4 3 2 
Sub 5 2 5 4 3 2 4 3 4 
Sub 15 2 2 1 1 1 4 5 4 
Sub 16 1 5 5 3 0 5 5 3 
Sub 19 3 5 3 2 2 3 2 1 
Sub 20 1 2 2 2 2 3 2 0 






Raw data set 6: Shin muscle soreness score 
High Estrogen Group (H) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 1 2 1 1 1 1 0 
 
0 
Sub 6 0 1 1 0 0 2 0 0 
Sub 9 2 4 3 1 1 2 2 2 
Sub 10 2 4 3 2 1 1 2 2 
Sub 18 0 1 0 0 0 0 0 0 
Sub 22 1 1 1 0 0 1 1 1 
         Low Estrogen Group (L) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 3 3 1 2 1 0 3 2 0 
Sub 5 1 3 4 3 2 3 2 2 
Sub 15 2 5 5 3 1 0 1 1 
Sub 16 0 5 5 2 0 5 3 3 
Sub 19 0 4 4 3 1 2 3 2 
Sub 20 2 2 0 0 0 2 1 1 






Raw data set 7: Calf muscle soreness score 
High Estrogen Group (H) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 1 2 1 1 1 2 1 
 
1 
Sub 6 1 4 2 1 1 1 1 1 
Sub 9 1 4 4 1 2 4 1 1 
Sub 10 2 4 3 2 1 1 2 2 
Sub 18 2 1 0 0 0 2 0 0 
Sub 22 3 5 4 3 1 4 4 2 
         Low Estrogen Group (L) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 3 2 1 0 1 0 3 3 1 
Sub 5 1 3 6 4 4 5 4 3 
Sub 15 3 4 4 3 1 2 4 2 
Sub 16 1 1 2 0 0 3 4 3 
Sub 19 1 3 2 1 2 3 1 0 
Sub 20 4 5 4 4 4 4 4 3 






Raw data set 8: CK activity (U/L) 
High Estrogen Group (H) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 1 32.3 124.9 42.9 62.6 34.9 40.1 
 
26.6 
Sub 6 34.4 133.8 73.8 70.1 57.9 127.9 64.1 43.6 
Sub 9 39.2 238.2 225.6 328.6 52.0 71.3 48.1 39.2 
Sub 10 49.5 742.7 328.1 315.5 25.7 104.2 50.3 42.5 
Sub 18 111.8 382.6 235.1 454.2 61.7 487.3 172.3 152.5 
Sub 22 46.1 231.2 133.4 238.3 32.6 71.3 49.4 49.4 
         Low Estrogen Group (L) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 3 44.4 330.1 188.5 179.8 78.8 151.9 95.0 75.3 
Sub 5 234.5 382.9 185.5 138.2 213.9 255.0 146.9 141.5 
Sub 15 128.3 983.6 501.0 274.1 142.0 337.1 252.0 142.8 
Sub 16 38.1 170.2 98.8 58.4 36.0 85.2 44.4 44.6 
Sub 19 39.2 122.5 82.6 192.7 32.6 56.1 58.0 71.7 
Sub 20 139.3 860.2 452.2 495.9 186.9 647.5 336.9 217.2 






Raw data set 9: Thigh circumference (cm) 
High Estrogen Group (H) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 1 57.2 56.3 56.0 56.3 56.7 56.6 
 
56.5 
Sub 6 45.9 45.5 48.1 45.7 45.7 45.2 45.0 45.1 
Sub 9 48.2 48.4 48.3 48.4 48.2 48.7 48.8 49.3 
Sub 10 49.8 50.3 49.7 50.0 48.7 49.5 48.8 48.9 
Sub 18 47.2 47.1 46.9 47.6 47.9 47.7 47.5 47.5 
Sub 22 49.6 49.4 49.0 48.8 48.5 48.8 48.8 48.6 
         Low Estrogen Group (L) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 3 45.7 46.1 46.6 48.6 46.3 47.4 46.9 47.4 
Sub 5 42.4 42.7 43.2 43.0 42.7 42.8 42.7 43.2 
Sub 15 39.2 39.9 41.0 40.9 40.1 40.2 40.6 40.0 
Sub 16 45.6 45.5 45.6 45.8 45.4 46.2 46.0 46.9 
Sub 19 44.9 44.7 45.1 45.1 46.8 45.6 46.3 45.1 
Sub 20 49.9 50.6 51.0 50.3 49.8 49.3 48.9 49.2 






Raw data set 10: Calf circumference (cm) 
High Estrogen Group (H) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 1 42.1 42.0 41.6 41.6 41.4 41.2 
 
41.4 
Sub 6 36.7 36.9 36.7 36.9 35.2 35.6 35.2 35.6 
Sub 9 37.4 38.0 37.3 37.4 37.3 37.6 37.5 37.5 
Sub 10 35.1 35.8 35.5 35.4 35.5 35.8 35.3 35.8 
Sub 18 34.8 34.6 34.8 34.5 35.1 35.5 34.9 35.2 
Sub 22 38.2 38.2 38.8 38.5 38.2 37.8 38.2 37.7 
         Low Estrogen Group (L) 
Sub ID D1PRE D1T24 D1T48 D1T72 D2PRE D2T24 D2T48 D2T72 
Sub 3 34.4 34.2 34.5 34.4 33.9 33.8 34.0 34.1 
Sub 5 33.5 33.3 33.5 33.3 33.7 33.5 33.7 33.6 
Sub 15 31.6 32.3 32.1 32.1 32.1 32.7 32.6 32.1 
Sub 16 36.1 36.5 36.2 36.5 36.0 36.2 36.3 36.6 
Sub 19 33.9 33.7 34.3 33.9 33.5 33.6 34.0 33.7 
Sub 20 35.5 36.1 36.4 36.1 36.4 36.8 36.3 36.1 






Raw data set 11: Knee extension peak torque (ft-lbs) 
High Estrogen Group (H) 
Sub ID D1PRE D1T72 D2PRE D2T72 
Sub 1 88 87 87 86 
Sub 6 99 55 84 73 
Sub 9 91 87 81 84 
Sub 10 86 69 61 70 
Sub 18 71 73 70 65 
Sub 22 59 59 70 74 
     Low Estrogen Group (L) 
Sub ID D1PRE D1T72 D2PRE D2T72 
Sub 3 91 98 97 92 
Sub 5 69 75 60 88 
Sub 15 64 48 48 46 
Sub 16 52 57 41 53 
Sub 19 55 67 65 68 
Sub 20 100 84 79 90 






Raw data set 12: Ankle dorsiflexion peak torque (ft-lbs) 
High Estrogen Group (H) 
Sub ID D1PRE D1T72 D2PRE D2T72 
Sub 1 21 36 39 36 
Sub 6 19 21 19 27 
Sub 9 30 30 33 24 
Sub 10 21 24 20 18 
Sub 18 39 43 51 41 
Sub 22 5 9 12 26 
     Low Estrogen Group (L) 
Sub ID D1PRE D1T72 D2PRE D2T72 
Sub 3 39 41 48 33 
Sub 5 24 28 25 59 
Sub 15 8 10 8 11 
Sub 16 16 13 18 22 
Sub 19 36 42 43 43 
Sub 20 32 43 48 61 
Sub 23 50 22 28 26 
 
